Journal: Frontiers in Pharmacology

Article Title: A full-spectrum Boswellia serrata extract with enhanced bioavailability, and its co-delivered system with curcumin alleviate pain and stiffness associated with moderate spondylitis: a randomized double-blind, placebo-controlled, 3-arm study

doi: 10.3389/fphar.2025.1577429

Figure Lengend Snippet: Mean change in (a) IL-1β and (b) NLRP3. Values are expressed as Mean ±SD, 2 × 3 repeated measures ANOVA was analysed to perform statistical significance.

Article Snippet: Serum concentrations of IL-1β (catalog no: E-EL-H0149) and NLRP3 (E-EL-H2557) were analyzed with the respective ELISA kits following the manufacturer’s instruction, (Elabscience, Biotechnology Co., Limited.

Techniques:

Journal: Microorganisms

Article Title: Transcriptomic and Immunopathological Profiles of Inflammasomes in Different Clinical Forms of American Cutaneous Leishmaniasis

doi: 10.3390/microorganisms13050980

Figure Lengend Snippet: Boxplots showing normalized gene expression data from RNA-seq of lesions in patients with different clinical forms of American Cutaneous Leishmaniasis caused by L. (L.) amazonensis and L. (V.) braziliensis. ADCL: Anergic Diffuse Cutaneous Leishmaniasis, caused by L. (L.) amazonensis ; LCL (La): Localized Cutaneous Leishmaniasis, caused by L. (L.) amazonensis ; LCL (Lb): Localized Cutaneous Leishmaniasis, caused by L. (V.) braziliensis ; and MCL: Mucocutaneous Leishmaniasis caused by L. (V.) braziliensis. A: NLRP3; B: AIM2; C: NLRP12; D: NLRC4; E: CASP1; F: CASP5; G: GSDMD; H: IL-18; I: IL-1 β. * = p < 0.05; ** = p < 0.001 and *** = p < 0.0001.

Article Snippet: The sections were incubated with primary antibodies anti-NLRP3 (polyclonal, E-AB-70161, Elabscience, Houston, TX, USA, 1:600), anti-AIM-2 (polyclonal, E-AB-10974, Elabscience, 1:100), anti-NLRC4 (polyclonal, E-AB-67860, Elabscience, 1:100), anti-NLRP12 (polyclonal, E-AB-66298, Elabscince, 1:500), anti-caspase-1 (monoclonal, G6231-3D2, Sigma Aldrich, St. Louis, MO, USA, 1:500), anti-caspase-5 (monoclonal, MAA770Hu22, Cloud-clone Corp., Katy, TX, USA, 1:100), anti-GSDMD (monoclonal, E-AB-81473, Elabscience, 1:200), anti-IL-1β (polyclonal, ab2105, Abcam, Cambridge, MA, USA, 1:800), and anti-IL-18 (polyclonal, ab68435, Abcam, 1:2000).

Techniques: Gene Expression, RNA Sequencing

Journal: Microorganisms

Article Title: Transcriptomic and Immunopathological Profiles of Inflammasomes in Different Clinical Forms of American Cutaneous Leishmaniasis

doi: 10.3390/microorganisms13050980

Figure Lengend Snippet: Immunohistochemistry reactions on histological sections of biopsies from patients with different clinical forms of ACL using anti-NLRP3, anti-AIM-2, anti-NLRP12, anti-NLRC4, anti-caspase-1, anti-caspase-5, anti-GSDMD, anti-IL-1β, and anti-IL-18 antibodies. ADCL: Anergic Diffuse Cutaneous Leishmaniasis caused by L. (L.) amazonensis ; LCL (La): Localized Cutaneous Leishmaniasis caused by L. (L.) amazonensis ; LCL (Lb): Localized Cutaneous Leishmaniasis caused by L. (V.) braziliensis ; MCL: Mucocutaneous Leishmaniasis caused by L. (V.) braziliensis . Red arrows indicate immunostained cells.

Article Snippet: The sections were incubated with primary antibodies anti-NLRP3 (polyclonal, E-AB-70161, Elabscience, Houston, TX, USA, 1:600), anti-AIM-2 (polyclonal, E-AB-10974, Elabscience, 1:100), anti-NLRC4 (polyclonal, E-AB-67860, Elabscience, 1:100), anti-NLRP12 (polyclonal, E-AB-66298, Elabscince, 1:500), anti-caspase-1 (monoclonal, G6231-3D2, Sigma Aldrich, St. Louis, MO, USA, 1:500), anti-caspase-5 (monoclonal, MAA770Hu22, Cloud-clone Corp., Katy, TX, USA, 1:100), anti-GSDMD (monoclonal, E-AB-81473, Elabscience, 1:200), anti-IL-1β (polyclonal, ab2105, Abcam, Cambridge, MA, USA, 1:800), and anti-IL-18 (polyclonal, ab68435, Abcam, 1:2000).

Techniques: Immunohistochemistry

Journal: Molecular Medicine Reports

Article Title: Effects of PYRIN-containing Apaf1-like protein 1 on isoflurane-induced postoperative cognitive dysfunction in aged rats

doi: 10.3892/mmr.2020.11244

Figure Lengend Snippet: PYPAF1-targeting shRNA mediates the downregulation of PYPAF1 expression in the hippocampus. Sprague-Dawley rats were injected with lentivirus carrying PYPAF1-shRNA or NC-shRNA by intracerebroventricular injection. (A) mRNA and (B) protein levels of PYPAF1 in the hippocampus were measured using reverse transcription-quantitative PCR and western blot analysis, respectively. ***P<0.001. NC, negative control; PYPAF1, PYRIN-containing Apaf1-like protein 1; shRNA, short hairpin RNA.

Article Snippet: The sections were dehydrated at 60°C in an incubator for 2 h, deparaffinized and heated in citric acid/sodium citrate solution at 95°C for 10 min. After blocking with goat serum (cat. no. SL038; Beijing Solarbio Science and Technology Co., Ltd.) for 15 min at room temperature, tissue sections were washed and incubated with PYPAF1 antibody (1:200; cat. no. NBP2-12446SS; Novus Biologicals, LLC) and ionized calcium binding adapter molecule-1 (Iba-1) antibody (1:200; cat.no. ab15690; Abcam) at 4°C overnight.

Techniques: shRNA, Expressing, Injection, Reverse Transcription, Real-time Polymerase Chain Reaction, Western Blot, Negative Control

Journal: Molecular Medicine Reports

Article Title: Effects of PYRIN-containing Apaf1-like protein 1 on isoflurane-induced postoperative cognitive dysfunction in aged rats

doi: 10.3892/mmr.2020.11244

Figure Lengend Snippet: PYPAF1 silencing alleviates cognitive dysfunction induced by isoflurane in rats. The spatial learning ability of rats was assessed using the Morris water maze. (A) Escape time, ***P<0.001 vs. control; # P<0.05, ## P<0.01 vs. isoflurane + shRNA NC. (B) Τimes of platform crossing and (C) retention time at target quadrant were recorded and analyzed. ***P<0.001. NC, negative control; PYPAF1, PYRIN-containing Apaf1-like protein 1; shRNA, short hairpin RNA.

Article Snippet: The sections were dehydrated at 60°C in an incubator for 2 h, deparaffinized and heated in citric acid/sodium citrate solution at 95°C for 10 min. After blocking with goat serum (cat. no. SL038; Beijing Solarbio Science and Technology Co., Ltd.) for 15 min at room temperature, tissue sections were washed and incubated with PYPAF1 antibody (1:200; cat. no. NBP2-12446SS; Novus Biologicals, LLC) and ionized calcium binding adapter molecule-1 (Iba-1) antibody (1:200; cat.no. ab15690; Abcam) at 4°C overnight.

Techniques: Control, shRNA, Negative Control

Journal: Molecular Medicine Reports

Article Title: Effects of PYRIN-containing Apaf1-like protein 1 on isoflurane-induced postoperative cognitive dysfunction in aged rats

doi: 10.3892/mmr.2020.11244

Figure Lengend Snippet: PYPAF1 silencing inhibits the activation of microglia. (A) mRNA levels of PYPAF1, and (B and C) protein levels of PYPAF1 and ASC in the hippocampus were measured using reverse transcription-quantitative PCR and western blot analysis on days 3 and 7 following isoflurane treatment, respectively. (B) Lane 1, control; lane 2, isoflurane; lane 3, isoflurane + shRNA-PYPAF1; lane 4, isoflurane + shRNA-NC. (D) Expression of PYPAF1 and Iba-1 in the hippocampus were determined using immunofluorescence assay. ***P<0.001. ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain; Iba-1, ionized calcium binding adapter molecule-1; Iso, isoflurane; NC, negative control; PYPAF1, PYRIN-containing Apaf1-like protein 1; shRNA, short hairpin RNA.

Article Snippet: The sections were dehydrated at 60°C in an incubator for 2 h, deparaffinized and heated in citric acid/sodium citrate solution at 95°C for 10 min. After blocking with goat serum (cat. no. SL038; Beijing Solarbio Science and Technology Co., Ltd.) for 15 min at room temperature, tissue sections were washed and incubated with PYPAF1 antibody (1:200; cat. no. NBP2-12446SS; Novus Biologicals, LLC) and ionized calcium binding adapter molecule-1 (Iba-1) antibody (1:200; cat.no. ab15690; Abcam) at 4°C overnight.

Techniques: Activation Assay, Reverse Transcription, Real-time Polymerase Chain Reaction, Western Blot, Control, shRNA, Expressing, Immunofluorescence, Binding Assay, Negative Control

Journal: Molecular Medicine Reports

Article Title: Effects of PYRIN-containing Apaf1-like protein 1 on isoflurane-induced postoperative cognitive dysfunction in aged rats

doi: 10.3892/mmr.2020.11244

Figure Lengend Snippet: PYPAF1 knockdown inhibits the activity of caspase-1, and expression of IL-1β and IL-18. (A) mRNA levels and (B) concentration of IL-1β and IL-18 in the hippocampus was determined using reverse transcription-quantitative PCR and ELISA, respectively, on day 3 following isoflurane treatment. (C) Activity of caspase-1 in the hippocampus was assessed using a commercial caspase-1 activity assay kit on day 3 following isoflurane treatment. ***P<0.001. IL, interleukin; NC, negative control; PYPAF1, PYRIN-containing Apaf1-like protein 1; shRNA, short hairpin RNA.

Article Snippet: The sections were dehydrated at 60°C in an incubator for 2 h, deparaffinized and heated in citric acid/sodium citrate solution at 95°C for 10 min. After blocking with goat serum (cat. no. SL038; Beijing Solarbio Science and Technology Co., Ltd.) for 15 min at room temperature, tissue sections were washed and incubated with PYPAF1 antibody (1:200; cat. no. NBP2-12446SS; Novus Biologicals, LLC) and ionized calcium binding adapter molecule-1 (Iba-1) antibody (1:200; cat.no. ab15690; Abcam) at 4°C overnight.

Techniques: Knockdown, Activity Assay, Expressing, Concentration Assay, Reverse Transcription, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Negative Control, shRNA

Journal: Molecular Medicine Reports

Article Title: Effects of PYRIN-containing Apaf1-like protein 1 on isoflurane-induced postoperative cognitive dysfunction in aged rats

doi: 10.3892/mmr.2020.11244

Figure Lengend Snippet: PYPAF1 silencing alleviates neuronal apoptosis. (A) Neuronal apoptosis in the hippocampus was determined using TUNEL-NeuN double staining on day 3 following isoflurane treatment. (B) Protein expression levels of Bcl-2, Bax and cleaved caspase-3 in the hippocampus were determined using western blot analysis. ***P<0.001. Iso, isoflurane; NC, negative control; PYPAF1, PYRIN-containing Apaf1-like protein 1; shRNA, short hairpin RNA.

Article Snippet: The sections were dehydrated at 60°C in an incubator for 2 h, deparaffinized and heated in citric acid/sodium citrate solution at 95°C for 10 min. After blocking with goat serum (cat. no. SL038; Beijing Solarbio Science and Technology Co., Ltd.) for 15 min at room temperature, tissue sections were washed and incubated with PYPAF1 antibody (1:200; cat. no. NBP2-12446SS; Novus Biologicals, LLC) and ionized calcium binding adapter molecule-1 (Iba-1) antibody (1:200; cat.no. ab15690; Abcam) at 4°C overnight.

Techniques: TUNEL Assay, Double Staining, Expressing, Western Blot, Negative Control, shRNA

Journal: Cancer Management and Research

Article Title:

NLRP3 Inflammasome Mediated Interleukin-1β Production in Cancer-Associated Fibroblast Contributes to ALA-PDT for Cutaneous Squamous Cell Carcinoma

doi: 10.2147/cmar.s226356

Figure Lengend Snippet: Figure 4 Production of IL1β occurs through activating NLRP3 inflammasome in an NF-κB-dependent manner. (A) Compared with the control, IL1β, NLRP3, caspase-1p20 and ASC all showed increased expression with time, esp in the 48hrs. (B) p-p65/p65 ratio increases with time. Control: CAFs were incubated with DMEM and without exposed to the light; Light: CAFs were incubated with DMEM for 5hrs at 37°C and exposed to the light; ALA: CAFs were incubated with ALA (0.5 mM) for 5h at 37°C, but not exposed to the light;12hrs/24hrs/ 48hrs: CAFs were incubated with ALA (0.5 mM) and exposed to the light. We collected the cell samples in 12hrs/24hrs/48hrs. Notes: *p<0.05; **p<0.01; ***p<0.001.

Article Snippet: Western Blot Analysis Production of NLRP3, ASC, Casp-1,IL1β, Phospho-NF-κB p65, NF-κB p65 in CAFs was determined by Western blotting using anti-NLRP3 antibody (NBP2-12446, Novus, 1:500), anti-ASC antibody (sc-271054, Santa Cruz Biotechnology, 1:200), anti- Casp-1 antibody (sc-56036, Santa Cruz Biotechnology, 1:200) and anti-IL1β antibody (ab9722, Abcam, 1:10000), anti- Phospho-NF-κB p65 antibody (3033s, Cell and Signaling, 1:1000), and anti-NF-κB p65 antibody (8242s, Cell and Signaling, 1:1000).

Techniques: Control, Expressing, Incubation